Intervention

Dolutegravir

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 51 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials51

Recruiting5

Common conditions25

Lead sponsors shown15

Clinical trials

51 shown

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyNCT05652478 · 2026-09-24

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsNCT06805656 · 2026-07-15

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionNCT06281834 · 2024-11-15

Doravirine Dose Optimisation in PregnancyNCT05630638 · 2023-10-10

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchNCT04892654 · 2022-08-17

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIVNCT07124559 · 2026-10-15

NOT_YET_RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311 · 2024-02-21

ACTIVE_NOT_RECRUITING

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in BotswanaNCT04862975 · 2024-01-09

Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)NCT05122767 · 2023-05-24

ACTIVE_NOT_RECRUITING

Pharmacokinetics and Safety of DolutegravIr in NeonateNCT05590325 · 2022-09-12

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersNCT04771754 · 2022-03-20

Drug Interactions Between Dolutegravir and Escalating Doses of RifampicinNCT04166474 · 2021-11-18

Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIVNCT04910711 · 2021-10-21

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsNCT04900038 · 2021-08-18

Gut Microbiota, PGx and INSTIs ResponseNCT04805944 · 2021-03-10

Inflammation and Co-Infections in D²EFTNCT04183738 · 2021-02-01

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive AdultsNCT04493216 · 2020-11-18

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.NCT03813979 · 2020-11-15

Second-line Switch to Dolutegravir StudyNCT04229290 · 2020-02-12

Dolutegravir in Real Life in LesothoNCT04238767 · 2020-02-10

Nucleosides And Darunavir/Dolutegravir In AfricaNCT03988452 · 2019-07-30

Effect on HIV Medications on EPC CellsNCT03782142 · 2018-11-01

Dolutegravir in Pregnant HIV Mothers and Their NeonatesNCT03249181 · 2018-01-22

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their InfantsNCT03048422 · 2018-01-19

Dolutegravir and Darunavir Evaluation in Adults Failing TherapyNCT03017872 · 2017-11-23

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionNCT02987530 · 2017-04-11

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and LamivudineNCT03078556 · 2017-03-27

Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV InfectionNCT02976259 · 2017-01-01

Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 InfectionNCT02551523 · 2016-11-01

ODYSSEY (PENTA 20)NCT02259127 · 2016-09-20

Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary TuberculosisNCT02583048 · 2016-08-15

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed PatientsNCT02572947 · 2016-06-01

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated ToxicityNCT02499978 · 2016-05-01

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176NCT02715479 · 2016-04-01

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionNCT02656511 · 2015-12-01

ACTIVE_NOT_RECRUITING

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing CureNCT02961829 · 2015-07-01

Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal DiseaseNCT02487706 · 2015-06-01

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based RegimenNCT02513147 · 2015-06-01

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted DarunavirNCT02337322 · 2015-03-31

The Dolutegravir Antiretroviral Mono-Therapy for HIV TrialNCT02401828 · 2015-03-01

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive AdultsNCT02218320 · 2014-10-01

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)NCT02098837 · 2014-04-01

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in GermanyNCT02076386 · 2014-03-04

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamNCT01827540 · 2013-03-01

Dolutegravir Expanded Access StudyNCT01536873 · 2012-06-14

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive SubjectsNCT01499199 · 2012-01-01

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and EthinylestradiolNCT01498861 · 2011-12-01

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.NCT01467518 · 2011-12-01

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsNCT01467531 · 2011-11-01

Drug Interaction Study Between Dolutegravir and PrednisoneNCT01425099 · 2011-09-01

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)NCT01263015 · 2011-02-01

Common conditions

Leading sponsors

ViiV Healthcare 13 National Institute of Allergy and Infectious Diseases (NIAID) 4 Chelsea and Westminster NHS Foundation Trust 2 Federal University of São Paulo 2 Kirby Institute 2 University of Liverpool 2 ANRS, Emerging Infectious Diseases 1 Botswana Harvard AIDS Institute Partnership 1 Brigham and Women's Hospital 1 Calmy Alexandra 1 Cliniques universitaires Saint-Luc- Université Catholique de Louvain 1 Desmond Tutu TB Centre 1 Duke University 1 Erasmus Medical Center 1 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 1

Trial status mix

COMPLETED31

UNKNOWN6

RECRUITING5

ACTIVE_NOT_RECRUITING3

WITHDRAWN3

TERMINATED2

NOT_YET_RECRUITING1

Phase mix

PHASE413

PHASE112

PHASE212

PHASE311

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.